

**For Immediate Release**

**Alembic Pharmaceuticals Limited  
Consolidated Results for quarter ended 30.06.2013**

**Revenues up by 16% at Rs 429 crores  
PBT up by 59% at Rs 61 crores**

**Editors Synopsis**

**Quarter ended 30<sup>th</sup> June, 2013**

- **Net sales up 16% at Rs 429 crores for the quarter against Rs. 368 crores in corresponding quarter last year**
- **PBT at Rs 61 crores, up by 59% from Rs 38 crores in corresponding quarter last year**
- **Domestic Branded formulations sales up by 15% for the quarter at Rs. 196 crores**
- **International generics sales up by 86% for the quarter at Rs. 85 crores**
- **EBITDA margin increased to 17% for the quarter from 14% in corresponding quarter last year**
- **Net profit after tax grew by 51% for the quarter at Rs. 47 crores vis-à-vis Rs. 31 crores in corresponding quarter last year**

**Vadodara, 7<sup>th</sup> Aug, 2013**

Alembic Pharmaceuticals Limited reported a 16% increase in revenues to Rs 429 crores for the quarter ended 30th June 2013, compared to Rs 368 crores in the corresponding quarter last year.

The Company posted 59% growth in Profit before Tax at Rs 61 crores for the quarter ended 30<sup>th</sup> June 2013 against Rs 38 crores posted in corresponding quarter last fiscal.

The Net Profit grew by 51% at Rs. 47 crores for the quarter ended 30<sup>th</sup> June 2013 against Rs. 31 crores in corresponding quarter last fiscal.

### **Domestic Branded Formulations Business**

The Domestic Branded Formulations business grew by 15% to Rs. 196 crores against Rs. 170 crores in the corresponding quarter of the previous year.

As per ORG IMS, Alembic has maintained market share of 1.79%.

Chronic and Acute segments grew by 26% and 3% respectively in current year (MAT-June 13) versus Industry growth rate of 12% and 7% respectively.

### **International Generics**

International generics grew by 86% to Rs. 85 crores against Rs. 46 crores over the corresponding quarter last year.

Desvenlafaxine Base Extended Release tablets has started receiving attention from key customers in US and sales is expected to get slowly ramp up in the next few quarters.

During the quarter 2 ANDA approvals were received. Cumulative ANDA/NDA filings at 57. Cumulative ANDA/NDA approvals now stands at 26.

## API

For the quarter, Export API recorded sales of Rs. 87 crores against Rs. 83 crores while domestic API recorded sales of Rs. 21 crores against Rs. 31 crores in corresponding quarter last year. Company filed one US DMF during the quarter. Cumulative filing now stand at 61.

Summary of total revenue (consolidated) for the quarter is as under:

(Rs. in crores)

Particulars	Q1 FY14	Q1 FY13	% Change
<b>Formulation</b>			
Domestic Branded	195.79	170.26	15%
Domestic Generic & NSA	25.43	26.98	(-)6%
International Generics	85.47	46.05	86%
International Branded	12.21	7.55	62%
<b>API</b>			
Domestic	20.21	30.47	(-)34%
International	86.76	83.48	4%
Export incentives & Others	2.90	3.27	
<b>Total</b>	<b>428.77</b>	<b>368.06</b>	<b>16%</b>

The Profit break-up for the quarter is as under:

(Rs. in crores)

Particulars	Q1 FY14	Q1 FY13	% Change
Operating Income	71.48	52.28	37%
Profit Before Tax	60.50	38.09	59%
Net Profit after Tax	46.64	30.83	51%

## About Alembic Pharmaceuticals Limited

Alembic Pharmaceuticals Limited, a vertically integrated research and development pharmaceutical company, has been at the forefront of healthcare since 1907. Headquartered in India, Alembic is a publicly listed company that manufactures and markets generic pharmaceutical products all over the world. Alembic's state of the art research and manufacturing facilities are approved by regulatory authorities all over the world including the US FDA. Alembic is one of the leaders in branded generics in India. Alembic's brands, marketed through a marketing team of over 3650 are well recognized by doctors and patients.

Information about the company can be found at [www.alembic-india.com](http://www.alembic-india.com); (reuters:ALEM.NS) (bloomberg:ALPM) (nse:APLLTD) (bse:533573)

### **For more information:**

**Mitanshu Shah**

**Phone: +91 265 – 3007630**

**Email: [mitanshu.shah@alembic.co.in](mailto:mitanshu.shah@alembic.co.in)**

**Alembic Pharmaceuticals Limited**